GENOVIS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.5 SEK | +9.83% |
|
+1.42% | -45.19% |
| Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
| Feb. 15 | Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | 155M 14.15M | Sales 2025 * | 238M 21.78M | Capitalization | 1.87B 171M |
|---|---|---|---|---|---|
| Net income 2024 * | 37M 3.38M | Net income 2025 * | 37M 3.38M | EV / Sales 2024 * | 11.3 x |
| Net cash position 2024 * | 120M 10.96M | Net cash position 2025 * | 93M 8.5M | EV / Sales 2025 * | 7.44 x |
| P/E ratio 2024 * |
49.6
x | P/E ratio 2025 * |
21.6
x | Employees | 37 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.42% |
More Fundamentals
* Assessed data
More news
| 1 day | +9.83% | ||
| 1 week | +1.42% | ||
| Current month | -14.67% | ||
| 1 month | -12.31% | ||
| 3 months | -44.77% | ||
| 6 months | -31.16% | ||
| Current year | -45.19% |
1 week
25.65
28.50
1 month
25.6537.00
Current year
25.6553.80
1 year
25.6566.90
3 years
25.6590.00
5 years
15.6590.00
10 years
1.2690.00
| Managers | Title | Age | Since |
|---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 72 | 20-05-04 | |
| Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 28.5 | +9.83% | 168,012 |
| 24-04-25 | 25.95 | -3.53% | 96,355 |
| 24-04-24 | 26.9 | -2.71% | 273,179 |
| 24-04-23 | 27.65 | +2.79% | 42,521 |
| 24-04-22 | 26.9 | -4.27% | 73,598 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT
More quotes
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
28.5
SEK
Average target price
50.5
SEK
Spread / Average Target
+77.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.19% | 156M | |
| +0.89% | 12.59B | |
| -10.29% | 7.42B | |
| +1.78% | 5.35B | |
| -1.16% | 4.51B | |
| +5.74% | 4.47B | |
| -50.70% | 3.21B | |
| +12.21% | 2.71B | |
| -16.13% | 1.96B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- GENO Stock
